MWNA
ARRY

Marshall Wace North America’s Array Biopharma Inc ARRY Stock Holding History

Marshall Wace North America’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2,554,381
Closed -$62.3M – 1869
2019
Q1 		$62.3M Buy
2,554,381
+2,541,301
+19,429% +$52.9M 0.44% 66
2018
Q4 		$186K Buy
+13,080
New +$198K ﹤0.01% 969
2017
Q3 		– Sell
-677,109
Closed -$5.42M – 1639
2017
Q2 		$5.42M Buy
677,109
+29,543
+5% +$242K 0.04% 477
2017
Q1 		$5.83M Buy
+647,566
New +$6.89M 0.05% 363

Other funds holding ARRY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace North America's ARRY Position: Q2 2019 in Review

Marshall Wace North America sold out of Array Biopharma Inc (ARRY) in Q2 2019, closing a stake of 2,554,381 shares — an estimated $62.3M sold.

Marshall Wace North America first reported a position in ARRY in Q1 2017 and held it in 4 quarters. The position peaked at $62.3M in Q1 2019. 318 funds tracked by Wall St. Rank hold ARRY as of Q2 2019.

  • Marshall Wace North America reported no remaining Array Biopharma Inc position as of Q2 2019 after selling out during the quarter.
  • Marshall Wace North America sold 2,554,381 Array Biopharma Inc shares in Q2 2019, an estimated $62.3M.
  • Marshall Wace North America first reported a position in Array Biopharma Inc in Q1 2017 and held it in 4 quarters.
  • Marshall Wace North America's Array Biopharma Inc position peaked at $62.3M in Q1 2019.
  • 318 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q2 2019.

Based on Marshall Wace North America's 13F filing for Q2 2019, filed 14 Aug 2019.